GBA Presents: RADIO SAVANT-!

oooopha PE under 7. You know we are going to run into value traps.. zombie stocks but Berry is not one of them.

Berry Global Is Now Trading At 7 Times Earnings And A 17% FCF Yield
Sep. 24, 2022 11:35 AM ETBerry Global Group, Inc. (BERY)8 Comments
Summary
  • Berry Global is a large producer of plastic packaging solutions.
  • The underlying cash flows remain very strong. Berry expects to generate $750M in free cash flow this year.
  • This includes a non-recurring $150M investment in the working capital and supply chain issues.
  • GBA UPGRADE TO BUY- BERY // Berry Global @ $47.45 <-----------------








VZ I used Berry from the late $40's and got out in the $58 area.

It had a nice run now what? I see the cup with a handle and if you back out there is a huge
cup with a handle as well... Double cups?

It is a name perhaps best viewed from the sidelines until they report.But a move eventually to $70 is in the cards.

The sector is still strong. Packaging multiples are well off their lows relative to the S&P, but remain at a discount to pre-pandemic levels.~si
 
A) Never got my 2nd email had to just call him.!

B) He did spot an large insider buy of $1 mil dollars worth in the $8 range.

C) I really like the chart

D) Fire side Chat next week who has a fire side chat with bad or boring news?

E) Recent upgrades street likes their prospects.

f) Near 40% pullback from recent move.

CHILDREN DANCE IN THE RAIN WITH ME!
 
BOND YIELDS HAVE SLIPPED KICKING OFF BIO-------

Rain Oncology resumed with a buy at Roth Capital on liposarcoma candidate milademetan

Jan. 31, 2023 10:48 AM ET Rain Oncology Inc. (RAIN)

  • Roth Capital has resumed coverage of Rain Oncology (NASDAQ:RAIN) with a buy rating saying that the company's lead candidate, milademetan for liposarcoma, has a positive risk/reward setup in advance of a Q1 data readout
  • The firm has a price target of $21 (~117% upside based on Monday's close).
  • Analyst Kumaraguru Raja noted that milademetan has its biggest potential in cancers where MDM2 and p53 are key drivers. MDM2 is an oncogene that modulates p53, a tumor suppressor.
  • Raja added that preclinical data shows that MDM2 could be a target for inflammatory and autoimmune diseases as well.
 
I think you said the same thing when I brought STLD to GBA at $50 a year or so ago.
:p



YIKES! STLD IS SUCH A MONSTER. I still have some in 1 acct but I blew out everything. Mistake. I guess they are similar in that they are commodities in a way and have competition and trying to go green etc. They are similar. I like BERY's management.

STLD Steel Dynamics, Inc.

$124.85 4.21 (+3.49%)3:15 PM 02/01/23
 
KEEP THEM EMAILS COMING!!!!!

HERE WE GO MAC...! GET READY TO GET RICH!!!!!!!

Expedia Group, Inc. (EXPE)
NasdaqGS - NasdaqGS Real Time Price.
117.89+3.59 (+3.14%)
As of 03:35PM EST.
 
  • Like
Reactions: mac
Those following along with Rain Therapeutics Inc. (NASDAQ:RAIN) will no doubt be intrigued by the recent purchase of shares by Franklin Berger, lead Independent Director of the company, who spent a stonking US$988k on stock at an average price of US$8.10. Aside from being a solid chunk in its own right, the deft move also saw their holding increase by some 14%.

Rain Therapeutics Insider Transactions Over The Last Year
In fact, the recent purchase by Franklin Berger was the biggest purchase of Rain Therapeutics shares made by an insider individual in the last twelve months,
 
Back
Top